Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Nov 15;37(12):933-942.
doi: 10.1093/ajh/hpae098.

Cardio-Rheumatology Insights Into Hypertension: Intersection of Inflammation, Arteries, and Heart

Shadi Akhtari  1   2   3 , Paula J Harvey  1   2   3 , Lihi Eder  4   2   3
Affiliations
Review

Cardio-Rheumatology Insights Into Hypertension: Intersection of Inflammation, Arteries, and Heart

Shadi Akhtari et al. Am J Hypertens. .

Abstract

There is an increased prevalence of atherosclerotic cardiovascular disease (ASCVD) in patients with inflammatory rheumatic diseases (IRD) including rheumatoid arthritis, systemic lupus erythematosus, psoriatic arthritis, and systemic sclerosis. The mechanism for the development of ASCVD in these conditions has been linked not only to a higher prevalence and undertreatment of traditional cardiovascular (CV) risk factors but importantly to chronic inflammation and a dysregulated immune system which contribute to impaired endothelial and microvascular function, factors that may contribute to accelerated atherosclerosis. Accurate ASCVD risk stratification and optimal risk management remain challenging in this population with many barriers that include lack of validated risk calculators, the remitting and relapsing nature of underlying disease, deleterious effect of medications used to manage rheumatic diseases, multimorbidity, decreased mobility due to joint pain, and lack of clarity about who bears the responsibility of performing CV risk assessment and management (rheumatologist vs. primary care provider vs. cardiologist). Despite recent advances in this field, there remain significant gaps in knowledge regarding the best diagnostic and management approach. The evolving field of Cardio-Rheumatology focuses on optimization of cardiovascular care and research in this patient population through collaboration and coordination of care between rheumatologists, cardiologists, radiologists, and primary care providers. This review aims to provide an overview of current state of knowledge about ASCVD risk stratification in patients with IRD, contributing factors including effect of medications, and review of the current recommendations for cardiovascular risk management in patients with inflammatory disease with a focus on hypertension as a key risk factor.

Keywords: atherosclerotic cardiovascular risk; cardio-rheumatology; hypertension; inflammation; inflammatory rheumatic diseases.

PubMed Disclaimer

Conflict of interest statement

S.A.: Honoraria: AbbVie and Novartis; P.J.H.: Honoraria for Continuing Medical Education from AbbVie and unrestricted grant funding support from Bios; L.E.: AbbVie, Novartis, UCB, Eli Lilly, Pfizer, Fresenius Kabi, BMS, Janssen—Advisory board/consult and grants.

Figures

Figure 1.
Figure 1.
Range of cardiovascular problems in inflammatory rheumatic diseases. ASCVD, atherosclerotic cardiovascular disease; ACS, acute coronary syndromes; CHF, congestive heart failure; HfrEF, heart failure with reduced ejection fraction; HfpEF, heart failure with preserved ejection fraction.
Figure 2.
Figure 2.
Risk factors for atherosclerotic cardiovascular disease in patients with inflammatory rheumatic diseases.
Figure 3.
Figure 3.
Factors contributing to the development of hypertension in inflammatory rheumatic diseases; RAAS, renin–angiotensin–aldosterone system.
See this image and copyright information in PMC

References

    1. Vaduganathan M, Mensah GA, Turco JV, Fuster V, Roth GA.. The global burden of cardiovascular diseases and risk: a compass for future health. J Am Coll Cardiol 2022; 80:2361–2371. - PubMed
    1. Avina-Zubieta JA, Thomas J, Sadatsafavi M, Lehman AJ, Lacaille D.. Risk of incident cardiovascular events in patients with rheumatoid arthritis: a meta-analysis of observational studies. Ann Rheum Dis 2012; 71:1524–1529. - PubMed
    1. Manzi S, Meilahn EN, Rairie JE, Conte CG, Medsger TA Jr, Jansen-McWilliams L, D'Agostino RB, Kuller LH.. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am J Epidemiol 1997; 145:408–415. - PubMed
    1. Yafasova A, Fosbol EL, Schou M, Baslund B, Faurschou M, Docherty KF, Jhund PS, McMurray JJV, Sun G, Kristensen SL, Torp-Pedersen C, Køber L, Butt JH.. Long-term cardiovascular outcomes in systemic lupus erythematosus. J Am Coll Cardiol 2021; 77:1717–1727. - PubMed
    1. Ciftci O, Yilmaz S, Topcu S, Caliskan M, Gullu H, Erdogan D, Pamuk BO, Yildirir A, Muderrisoglu H.. Impaired coronary microvascular function and increased intima-media thickness in rheumatoid arthritis. Atherosclerosis 2008; 198:332–337. - PubMed

MeSH terms

Substances